Supplementary Data from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)